Immvira Co., Ltd.

The turn of the year witnessed a spike in venture capital and private equity funding deals in China, with several valued at around the $100m level. A string of four large financings around late Decemb

Bolt-on acquisitions and mergers between Chinese biotechs and major drug makers had not yet come into fashion over the past year, although the two groups continued to pursue tie-ups in their efforts t

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. TiumBio, Hansoh Ink $170m Endometr

Venture capital investment in biopharmaceutical companies has been remarkable throughout 2020, both in terms of individual company fundraisings and new VC funds, including two funds totaling $755m tha